icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
CERTAIN-1: Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection With and Without Cirrhosis
 
 
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
 
Kazuaki Chayama1, Fumitaka Suzuki2, Yoshiyasu Karino3, Yoshiiku Kawakami1, Ken Sato4, Tomofumi Atarashi5, Atsushi Naganuma6, Tsunamasa Watanabe7, Yuichiro Eguchi8, Hitoshi Yoshiji9, Masataka Seike10, Yoshiyuki Takei11, Koji Kato12, Kati a Alves12, Margaret Burroughs12, Rebecca Redman12, David L Pugatch12, Tami J Pilot-Mati as12, Wangang Xie12, Hiromitsu Kumada2
1Hiroshima University Hospital, Hiroshima, Japan; 2Toranomon Hospital, Tokyo, Japan; 3JA Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital, Sapporo, Japan; 4Gunma University Hospital, Maebashi, Japan; 5JA Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan; 6NHO Takasaki General Medical Center, Takasaki, Japan; 7St. Marianna University School of Medicine, Kawasaki, Japan; 8Saga University Hospital, Saga, Japan; 9Nara Medical University Hospital, Nara, Japan; 10Oita University Hospital, Yufu, Japan; 11Mie University Hospital, Mie, Japan; 12AbbVie Inc., North Chicago, Illinois, United States
 
EASL: ENDURANCE-3: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR COMPARED TO SOFOSBUVIR PLUS DACLATASVIR IN TREATMENT-NA¤VE HCV GENOTYPE 3-INFECTED PATIENTS WITHOUT CIRRHOSIS - (04/21/17)
 
EASL:
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (04/20/17)
 
EASL: EXPEDITION-I: Efficacy and Safety of Glecaprevir/Pibrentasvir for Treatment of Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection in Adults with Compensated Cirrhosis - (04/21/17)
 
EASL: High SVR Rates With Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis - (04/25/17)
 
EASL: MAGELLAN-2: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR IN LIVER OR RENAL TRANSPLANT ADULTS WITH CHRONIC HEPATITIS C GENOTYPE 1-6 INFECTION - (04/24/17)
 
EASL: Pooled Resistance Analysis in HCV Genotype 1-6 Infected Patients Treated With Glecaprevir/Pibrentasvir in Phase 2 and 3 Clinical Trials - (04/24/17)
 
EASL: Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection: An Integrated Analysis - (04/24/17)
 
EASL: MAGELLAN-1, PART 2: GLECAPREVIR/PIBRENTASVIR FOR 12 OR 16 WEEKS IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 AND PRIOR DIRECT-ACTING ANTIVIRAL TREATMENT FAILURE - (04/24/17)
 
EASL: Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis - (04/21/17)

0501171

0501172

0501173

0501174

0501175

0501176

0501177

0501178